recombinant activated factor VII

DRUG5 trials

Conditions

Blood Coagulation DisordersCardiopulmonary BypassCoronary Artery DiseaseHeart Valve DiseasesHemophilia A With InhibitorsIntracerebral HemorrhageMyocardial IschemiaVon Willebrand Disease, Type 3

Phase 2

The Spot Sign for Predicting and Treating ICH Growth Study

CompletedNCT00810888

University of CincinnatiIntracerebral Hemorrhage

Start: 2010-11-30End: 2016-04-30Updated: 2018-03-16

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

NCT01105546

Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoHemophilia A With Inhibitors

Start: 2010-12-31End: 2014-04-30Target: 50Updated: 2013-04-08

Phase 3

Salvage Use of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery

NCT00214656

Austin HealthBlood Coagulation Disorders, Coronary Artery Disease, Heart Valve Diseases +1

Start: 2005-06-30End: 2008-06-30Target: 40Updated: 2005-09-22

Unknown Phase

Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass

CompletedNCT01352143

Emory UniversityCardiopulmonary Bypass

Start: 2011-03-31End: 2012-06-30Updated: 2013-11-20

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

RecruitingNCT06883240

Hoffmann-La RocheVon Willebrand Disease, Type 3

Start: 2025-04-29End: 2026-11-01Target: 40Updated: 2026-03-18

Related Papers

Clinical Features, Non-Contrast CT Radiomic and Radiological Signs in Models for the Prediction of Hematoma Expansion in Intracerebral Hemorrhage

Canadian Association of Radiologists Journal2023-04-183 citations

Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign–Positive Acute Intracerebral Hemorrhage